Skip Nav Destination
Issues
1 May 2015
-
Cover Image
Cover Image
Using a mouse model of breast cancer driven by Trp53 loss, Zhang and colleagues investigated the functional interaction between CD29hiCD24hi tumor-initiating cells (TIC) and a mesenchymal-like CD29hiCD24lo tumor cell subpopulation. These CD29hiCD24lo niche cells promoted the self-renewal capacity of TICs via secretion of soluble factors including WNT2 and chemokine (C-X-C motif) ligand 12 (CXCL12). Depletion of WNT2 and CXCL12 in CD29hiCD24lo niche cells or of the corresponding receptors in TICs impaired the ability of CD29hiCD24lo cells to promote TIC self-renewal in vitro. Furthermore, in limiting dilution transplantation assays, CD29hiCD24lo niche cells enhanced the tumor-initiating potential of TICs, which was decreased by knockdown of WNT2 in the CD29hiCD24lo subpopulation. These data highlight the importance of paracrine crosstalk between different tumor cell subpopulations in promoting tumor initiation. For details, please see the article by Zhang and colleagues on page 520. - PDF Icon PDF LinkTable of Contents
ISSN 2159-8274
EISSN 2159-8290
Issue Sections
In This Issue
In the Spotlight
Review
Research Articles
Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers
Johnathan Watkins; Daniel Weekes; Vandna Shah; Patrycja Gazinska; Shalaka Joshi; Bhavna Sidhu; Cheryl Gillett; Sarah Pinder; Fabio Vanoli; Maria Jasin; Markus Mayrhofer; Anders Isaksson; Maggie C.U. Cheang; Hasan Mirza; Jessica Frankum; Christopher J. Lord; Alan Ashworth; Shaveta Vinayak; James M. Ford; Melinda L. Telli; Anita Grigoriadis; Andrew N.J. Tutt
Suppression of Early Hematogenous Dissemination of Human Breast Cancer Cells to Bone Marrow by Retinoic Acid–Induced 2
Stefan Werner; Benedikt Brors; Julia Eick; Elsa Marques; Vivian Pogenberg; Annabel Parret; Dirk Kemming; Antony W. Wood; Henrik Edgren; Hans Neubauer; Thomas Streichert; Sabine Riethdorf; Upasana Bedi; Irène Baccelli; Manfred Jücker; Roland Eils; Tanja Fehm; Andreas Trumpp; Steven A. Johnsen; Juha Klefström; Matthias Wilmanns; Volkmar Müller; Klaus Pantel; Harriet Wikman
Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor–Driven Lung Adenocarcinoma
Tapan K. Maity; Abhilash Venugopalan; Ilona Linnoila; Constance M. Cultraro; Andreas Giannakou; Roxanne Nemati; Xu Zhang; Joshua D. Webster; Daniel Ritt; Sarani Ghosal; Heinz Hoschuetzky; R. Mark Simpson; Romi Biswas; Katerina Politi; Deborah K. Morrison; Harold E. Varmus; Udayan Guha
Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis
Andrea Lunardi; Shohreh Varmeh; Ming Chen; Riccardo Taulli; Jlenia Guarnerio; Ugo Ala; Nina Seitzer; Tomoki Ishikawa; Brett S. Carver; Robin M. Hobbs; Valentina Quarantotti; Christopher Ng; Alice H. Berger; Caterina Nardella; Laura Poliseno; Rodolfo Montironi; Mireia Castillo-Martin; Carlos Cordon-Cardo; Sabina Signoretti; Pier Paolo Pandolfi
News in Brief
News in Depth
Research Watch
Autophagy
Clinical Trials
DNA Repair
Drug Resistance
Epigenetics
Immunotherapy
Leukemia
Metastasis
Personalized Medicine
Prostate Cancer
Targeted Therapy
Transcription Factors
Tumor Suppressors
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.